Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
ACTON, Mass./WEST WARWICK, R.I., February 16, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets.
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the quarter ended March 31, 2022.
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test
Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the quarter ended March 31, 2022.
Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced…